Magnetic Resonance Imaging Clinical Trial
Official title:
A Multicenter, Open-label, Phase III Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects Referred for Contrast-enhanced MRI of the Central Nervous System (CNS)
Verified date | September 2014 |
Source | Bayer |
Contact | n/a |
Is FDA regulated | No |
Health authority | Japan: Pharmaceuticals and Medical Devices Agency |
Study type | Interventional |
Purpose of the study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking images of the brain and spine. The results of the Magnetic Resonance Imaging (MRI) will be compared to the results of images taken without contrast (gadobutrol).
Status | Completed |
Enrollment | 223 |
Est. completion date | August 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects referred for a contrast-enhanced Magnetic Resonance Imaging (MRI) of the central nervous system based on current clinical symptoms or results of a previous imaging procedure Exclusion Criteria: - Subjects with any contraindication to the MRI examination - Subjects with severe renal disease to end stage renal disease - Subjects scheduled or are likely to require a biopsy or any interventional therapeutic procedure within 72 (±4) hours after the study MRI |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Bayer |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Scores for visualization parameter: degree of contrast enhancement | Blinded readers evaluate contrast of at maximum 5 lesions and 4 normal brain structures in scans taken with and without injection of gadobutrol on a 4-point-scale. | Day of gadobutrol injection (Day 0) | No |
Primary | Scores for visualization parameter: border delineation | Blinded readers evaluate border delineation of at maximum 5 lesions and 4 normal brain structures in scans taken with and without injection of gadobutrol on a 4-point-scale. | Day of gadobutrol injection (Day 0) | No |
Primary | Scores for visualization parameter: internal morphology | Blinded readers evaluate internal morphology of at maximum 5 lesions and 4 normal structures in scans taken with and without gadobutrol on a 3-point-scale. | Day of gadobutrol injection (Day 0) | No |
Primary | Number of detected lesions | Blinded readers determine number of detected lesions in scans with and without gadobutrol. | Day of gadobutrol injection (Day 0) | No |
Secondary | Percentage of exact match of the MRI diagnosis with the final clinical diagnosis | An exact match is defined as identical diagnosis given by the blinded reader and the independent standard of truth committee. | Day of gadobutrol injection (Day 0) | No |
Secondary | Sensitivity and specificity to detect abnormal/normal brain tissue | Blinded readers classify the brain tissue as normal or abnormal based on the MRI sets. | Day of gadobutrol injection (Day 0) | No |
Secondary | Sensitivity and specificity to detect malignant Central Nervous System(CNS) lesions | Percentage to correctly detect presence and absence of malignant lesions which are derived from the MR diagnosis of readers when compared with the diagnosis of the independent standard of truth committee. | Day of gadobutrol injection (Day 0) | No |
Secondary | Number of participants with treatment emergent adverse events as a measure of safety and tolerability | 3 days after injection (Day 3) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03785171 -
Predicative Value of Multimodal MRI in Moyamoya Disease
|
||
Not yet recruiting |
NCT03726788 -
Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis
|
Phase 2 | |
Active, not recruiting |
NCT01956409 -
Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis
|
Phase 4 | |
Recruiting |
NCT03635619 -
The Application of 3T MRI in Esophageal Cancer
|
||
Recruiting |
NCT03658343 -
T2* MRI Analysis for Sarcoma
|
N/A | |
Recruiting |
NCT04555642 -
Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
|
||
Active, not recruiting |
NCT03441867 -
Neuroimaging Biomarker for Seizures
|
N/A | |
Recruiting |
NCT04850001 -
Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study
|
||
Not yet recruiting |
NCT05816213 -
Point-of-care Low-field MRI in Acute Stroke
|
||
Active, not recruiting |
NCT05498623 -
MR Fingerprinting for Diagnostic of Prostate Cancer
|
||
Recruiting |
NCT04996615 -
Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
|
||
Recruiting |
NCT04257747 -
Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI
|
N/A | |
Recruiting |
NCT05889117 -
Brain Stimulation for Concussion
|
N/A | |
Completed |
NCT02540967 -
Drug Use Investigation of Gadovist.
|
||
Completed |
NCT05103189 -
4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension
|
N/A | |
Completed |
NCT02567318 -
Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia?
|
N/A | |
Recruiting |
NCT02834585 -
Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT)
|
N/A | |
Active, not recruiting |
NCT02446665 -
Disease Status in Primary Sclerosing Cholangitis by Elastography
|
N/A | |
Completed |
NCT01721785 -
Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer
|
N/A | |
Completed |
NCT01223404 -
Nicotinic Modulation of the Default Network
|
N/A |